The fact that it can simultaneously suppress two fundamental pathways, mTORC1 in CM and TGFβ1 in cardiac fibroblasts, posits PIP4k2c as a key target for regulating CH and CF in HF patients. This evidence concerns the gene PIP4K2C and cyclic hematopoiesis.